Close Menu
    What's Hot

    Has Bitcoin been captured by politics and institutions?

    TakeOver Successfully Hosts Second Annual BitGala Celebrating Bitcoin In Las Vegas

    Metaplanet Continues $5.4B Bitcoin Buying Plan as Holdings Pass 8,000 BTC

    Facebook X (Twitter) Instagram
    MarketsNews.co.uk
    • Live Chart
    • Brokers
    • Scam Broker
    • Reviews
    • Tools
      • Lot Size Calculator
      • Margin Calculator
      • PIPS Calculator
      • Profit & loss calculator
    Facebook X (Twitter) Instagram
    Start Trading
    Trending Topics:
    • Markets
    • Stocks
    • Cryptocurrency
    • Forex
    • Scam Broker
    MarketsNews.co.uk
    • Markets
    • Stocks
    • Cryptocurrency
    • Forex
    • Scam Broker
    Markets

    Hair loss drug probed in Europe over link to suicidal thoughts

    Anthony M. OrbisonBy Anthony M. OrbisonOctober 4, 2024No Comments2 Mins Read
    Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
    Hair loss drug probed in Europe over link to suicidal
    Hair loss drug probed in Europe over link to suicidal
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Europe’s medicines regulator has started a review of whether a drug used to treat male balding can be linked to suicidal thoughts and behaviors. 

    The European Medicines Agency’s review of finasteride, which is available as both a pill and a solution that can be applied directly to the skin, follows concerns being raised about the potential link between the drug and thoughts of suicide. Finasteride can also be used to treat men with an enlarged prostate. Another drug, called dutasteride, also used to treat an enlarged prostate, is similarly under review by the EMA. 

    Drugs containing finasteride and dutasteride when taken by mouth have a “known risk of psychiatric side effects, including depression,” said the regulator in a statement. Suicidal ideation has already been added as a possible side effect in the product information for two drugs containing finasteride — Propecia and Proscar.

    Now, the EMA says it will review all the evidence to decide whether the authorizations for these drugs should be maintained, changed, suspended or withdrawn in the European Union.

    Meanwhile, Britain’s drug regulator told men taking finasteride to “stay vigilant” for potential psychiatric and sexual side effects. The UK’s Medicines and Healthcare products Regulatory Agency said in April that a new patient alert card would be introduced into finasteride packs this year. Only oral finasteride is authorized in the UK, not the topical product. 

    Generic finasteride is available from several manufactures, with brand name Proscar and Propecia both produced by Merck, known as MSD outside of North America.

    Recommended newsletter
    The Broadsheet: Covers the trends and issues impacting women in and out of the workplace and the women transforming the future of business.
    Sign up here.

    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
    Previous ArticleIndia’s Jio Financial, BlackRock get in-principle approval to set up mutual fund business By Reuters
    Next Article Ethereum’s identity crisis deepens as inflation returns, analyst warns
    Anthony M. Orbison
    • Website

    Related Posts

    Where Analysts Think Bitcoin is Headed in 2025

    December 23, 2024

    Fed says it is weighing changes to bank tests for systemic risk

    December 23, 2024

    Housing crisis: Mobile home prices soar faster than single-family homes

    December 23, 2024
    Leave A Reply Cancel Reply

    Amazon.com, Inc.
    $213.57
    $5.66
    2.72%
    Meta Platforms, Inc.
    $697.71
    $13.09
    1.91%
    S&P 500
    $6,000.36
    $61.06
    1.03%
    Alphabet Inc.
    $174.92
    $5.11
    3.01%
    EUR/USD
    $1.14
    $0.0056
    0.49%
    EUR/JPY
    $165.05
    $0.774
    0.47%
    USD/CAD
    $1.37
    $0.0017
    0.12%

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    We're social. Connect with us:

    Facebook X (Twitter)
    • Home
    • About us
    • Contact
    • Disclaimer
    • Privacy Policy
    © 2025 Marketsnews.co.uk

    Type above and press Enter to search. Press Esc to cancel.